1. https://www.unaids.org/en/resources/documents/2024/UNAIDS_FactSheet. Latest global and regional statistics on the status of the AIDS epidemic. 22 July 2024. Erişim tarihi: 31.07.2024.
2. Sağlık Bakanlığı. HIV-AIDS İstatistikleri. https://hsgm.saglik.gov.tr/depo/birimler/bulasici-hastaliklar-ve-erken-uyari-db/Dokumanlar/Istatistikler/hiv-aids-2023.pdf. Erişim tarihi:
31.07.2024.
3. Ananworanich J, Dubé K, Chomont N. How does the timing of antiretroviral therapy initiation in acute infection affect HIV reservoirs? Curr Opin HIV AIDS 2015; 10: 18–28.
4. Laanani M, Ghosn J, Essat A, Melard A, Seng R, Gousset M et al. Impact of the timing of initiation of antiretroviral therapy during primary HIV-1 infection on the decay of cell-associated
HIV-DNA. Clin Infect Dis 2015; 60: 1715–1721.
5. Suanzes P, Navarro J, Rando-Segura A, Álvarez-López P, García J, Descalzo V, et al. Impact of very early antiretroviral therapy during acute HIV infection on long-term immunovirological
outcomes. Int J Infect Dis 2023; 100–106.
6. Consolidated guidelines on differentiated HIV testing services. Geneva: World Health Organization; 2024. Licence: CC BY-NC-SA 3.0 IGO.
7. Clinical and Laboratory Standards Institute. Criteria for laboratory testing and diagnosis of human immunodeficiency virus infection; approved guideline. CLSI document M53-A. Wayne,
PA: Clinical and Laboratory Standards Institute; 2011.
8. Daar ES, Little SJ, Pitt J, Santangelo J, Ho P, Harawa N, et al. Diagnosis of primary HIV-1 infection. Ann Intern Med 2001;134:25–29.
9. Buttò S, Suligoi B, Fanales-Belasio E, Raimondo M. Laboratory diagnostics for HIV infection. Ann Ist super sAnItà 2010;46:24-33.
10. Fields Virology. Ed. Knipe DM, Howley PM. – 7th ed. Philadelphia, PA 19103, USA. Volume 3. HIV-1: Replication, Pathogenesis, Clinical Manifestations, and Treatment. Ed. Kuritzkes DR,
Koup RA, 2023.
11. Tomaras GD, Haynes BF. HIV-1 specific antibody responses during acute and chronic HIV-1 infection. Curr Opin HIV AIDS 2009; 4(5):373-9.
12. Keating SM, Pilcher CD, Jain V, Lebedeva M, Hampton D, Abdel-Mohsen M, et al. HIV antibody level as a marker of HIV persistance and low-level viral replication. J Infect Dis 2017; 216(1):
72-81.
13. Branson BM. The future of HIV testing. J Acquir Immune Defic Syndr 2010; 55: 102-105.
14. Fiebig EW, Wright DJ, Rawal BD, Garrett PE, Schumacher RT, Peddada L. Dynamics of HIV viremia and antibody seroconversion in plasma donors: implications for diagnosis and staging of
primary HIV infection. AIDS. 2003; 17(13):1871-9.
15. EACS Guidelines version 12.0, October 2023.
16. Alexander TS. Human immunodeficiency virus diagnostic testing: 30 years of evolution. Clin Vaccine Immunol 2016; 23:249 –253.
17. Demir T, Yalcin S, Kilic S. Evaluation of the diagnostic performance and optimal cutoff value of a fourth-generation ELISA, VIDAS HIV-1/2 Duo Ultra assay, in a low-prevalence country,
Diagnostic Microbiology and Infectious Disease. 2020; 97(1):115011.
18. Blaich A, Buser A, Stöckle M, Gehringer C, Hirsch HH, Battegay M, et al. Specificity of two HIV screening tests detecting simultaneously HIV-1 p24 antigen and antibodies to HIV-1 and −2.
J Virological Methods 2017; 249:143-146.
19. Centers for Disease Control and Prevention and Association of Public Health Laboratories. Laboratory Testing for the Diagnosis of HIV Infection: Updated Recommendations. http://dx.doi.
org/10.15620/cdc.23447. June 27, 2014. Erişim Tarihi: 27.07.2024.
20. Salmona M, Delarue S, Delaugerre C, Simon F, Maylin S. Clinical evaluation of BioPlex 2200 HIV Ag-Ab, an automated screening method providing discrete detection of HIV-1 p24 antigen,
HIV-1 antibody, and HIV-2 antibody. J Clin Microbiol 2014; 52(1): 103-107.
21. HIV/AIDS Tanı ve Tedavi Rehberi, 2019, Halk Sağlığı Genel Müdürlüğü, Sağlık Bakanlığı Yayın No 1133, Ankara, 2019.
22. Demir T, Yıldıran D, Kılıç S. Yeni HIV tanı algoritmasına geçiş sürecinde Ulusal HIV-AIDS Referans Merkezi’nin deneyimi: line-immunoassay test ve Bio-rad Geenius™ HIV-1/2 antikor ayırt
edici hızlı doğrulama testleri karşılaştırmalı analizi. Mikrobiyol Bul 2021;55(1):17-29.
23. Ly TD, Plantier JC, Leballais L, Gonzalo S, Lemée V, Laperche S. The variable sensitivity of HIV Ag/Ab combination assays in the detection of p24 Ag according to genotype could compromise
the diagnosis of early HIV infection. J Clin Virol 2012; 55: 121-127.
24. Zouhair S, Roussin-Bretagne S, Moreau A, Brunet S, Laperche S, Maniez M, et al. Group O human immunodeficiency virus type 1 infection that escaped detection in two immmunoassays. J
Clin Microbiol 2006; 44: 662–665.
25. Commission decision on common technical specifications for in vitro diagnostic medical devices. Off J Eur Commun 2009; L39: 3–49.
26. Ammassari A, Abbate I, Orchi N, Pinnetti C, Rozera G, Libertone R, et al. Acute HIV infection (AHI) in a specialized clinical setting: Case-finding, description of virological, epidemiological
and clinical characteristics. J Int AIDS Soc 2014; 17: 19676.
27. Barik SK, Mohanty KK, Bisht D, Joshi B, Jena S, Tripathy SP. An Overview of Enzyme Immunoassay: The Test Generation Assay in HIV/ AIDS Testing. J AIDS Clin Res 2018; 9:3.
28. Reida J, Van Zyla G, Linströma M, Korsmanb S, Maraisb G, Preisera W. High positive HIV serology results can still be false positive. IDCases 2020; 21:e00849.
29. Liu P, Jackson PShaw N, Heysell S. Spectrum of false positivity for the fourth generation human immunodeficiency virus diagnostic tests. AIDS Res Ther 2016; 13:1.
30. Campbell-Yesufu OT, Gandhi RT. Update on human immunodeficiency virus (HIV)-2 infection. Clin Infect Dis. 2011; 52(6): 780-7.
31. Güler E, Arıkan A, Abobakr M, Sayan M, Süer K, Şanlıdağ T. Positive anti-HIV ELISA results in pregnancy: is it reliable? Infect Dis Obstet Gynecol 2022; 2022:1157793.
32. CDC. False-positive HIV test results fact sheet. May 2018. https://www.cdc.gov/hiv/pdf/testing/cdc-hiv-factsheet-false-positive- test-results.pdf. Erişim Tarihi: 27.07.2024.
33. Almaguer AG, L Mendosa Flores L, Sánchez-López LA, Palau-Dávila LA, Padilla-Orozco M, Camacho-Ortiz A. Correlation between rapid HIV testing and fourth-generation ELISA results
for HIV detection among pregnant patients in the delivery room. Int J Gynecol Obstet 2017; 1–3.
34. Hardie DR, Korsman SN, Hsiao NY, Morobadi MD, Vawda S, Goedhals D. Contamination with HIV antibody may be responsible for false positive results in specimens tested on automated
platforms running HIV 4th generation assays in a region of high HIV prevalence. PLoS One 2017; 12: e0182167.
35. Hussain T, Sinha S, Katoch K, Yadav VS, Kulshreshtha KK, Singh I, et al. Serum samples from patients with mycobacterial infections cross-react with HIV structural proteins Gp41, p55 and
p18. Lepr Rev 2007;78:137–47.
36. Gasasira AF, Dorsey G, Kamya MR, Havlir D, Kiggundu M, Rosenthal PJ, et al. False-positive results of enzyme immunoassays for human immuno-deficiency virus in patients with uncomplicated
malaria. J Clin Microbiol 2006;44(8):3021–4.
37. Kiptinness C, Kuo AP, Reedy AM, Johnson CC, Ngure K, Wagner AD, et al. Examining the use of HIV self-testing to support PrEP delivery: a systematic literature review. Curr HIV/AIDS
Rep 2022;19:394-408.
38. Guidelines on long-acting injectable cabotegravir for HIV prevention. Geneva: World Health Organization; 2022 (https://www.who.int/publications/i/item/9789240054097. Erişim Traihi:
27.07.2024.
39. NYC reports spate of HIV false positives with oral test. CDC: tests still play important role. AIDS Alert 2008; 23:93-4.
40. Facente SN, Dowling T, Vittinghoff E, Sykes DL, Colfax GN. False positive rate of rapid oral fluid HIV tests increases as kits near expiration date. PLoS One 2009; 4:e8217.
41. Branson BM, Handsfield HH, Lampe MA, Janssen RS, Taylor AW, Lyss SB. Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settin-
gs. MMWR Recomm Rep 2006; 55(RR-14):1-17.
42. WHO recommends countries move away from the use of Western Blotting and Line Immunoassays in HIV testing strategies and algorithms. November 2019. WHO reference number WHO/
CDS/HIV/19.30.
43. WHO Prequalification of In Vitro Diagnostics PUBLIC REPORT Product: Xpert HIV-1 Qual XC https://extranet.who.int/prequal/sites/default/files/whopr_files/Xpert%20HIV-1%20
Qual%20XC%20%28PQDx%200652-070-00%29%20Public%20Report%20v%201.0%20.pdf
44. Campbell-Yesufu OT, Gandhi RT. Update on human immunodeficiency virus (HIV)-2 infection. Clin Infect Dis 2011; 52(6):780-7.
45. Technical Update for HIV Nucleic Acid Tests Approved for Diagnostic Purposes. https://www.cdc.gov/hiv/guidelines/recommendations/technical-update-for-hiv.html. Erişim tarihi:
27.7.2024
46. The Panel on Antiretroviral Therapy and Medical Management of HIV-Infected Children. Guidelines for the use of antiretroviral agents in pediatric HIV infection. http://aidsinfo.nih.gov/
ContentFiles/PediatricGuidelines.pdf. Erişim Tarihi: 27.07.2024.
47. Updated recommendations on first-line and second-line antiretroviral regimens and post-exposure prophylaxis and recommendations on early infant diagnosis of HIV. Geneva: World Health
Organization; 2018 (https://www.who.int/publications/i/item/WHO-CDS-HIV-18.51, Erişim tarihi: 27.07.2024.
48. FDA-Approved HIV Tests. Available at http://www.fda.gov/. Erişim tarihi: 27.07.2024.
49. Optimizing HIV testing algorithms: a generic verification protocol for selecting appropriate HIV serology assays and assessing the level of shared false reactivity. Geneva: World Health Or-
ganization; 2021. Licence: CC BY-NC-SA 3.0 IGO.
50. Center for Disease Controls and Prevention. Advantages and Disadvantages of FDA-Approved HIV Assays Used for Screening. cdc.gov. Available at https://www.cdc.gov/hiv/pdf/testing/
hiv-tests-advantages-disadvantages_1.pdf. June 2018; Erişim tarihi: 27.07.2024.
51. Smith D, Switzer WM, Peters P, Delaney KP, Granade TC, Masciotra S, et al. A Strategy for PrEP Clinicians to Manage Ambiguous HIV Test Results During Follow-up Visits Personal. Open
Forum Infect Dis 2018; 5(8).
52. Manak MM, Jagodzinski LL, Shutt A, Malia JA, Leos M, Ouellette J, et al. Decreased Seroreactivity in Individuals Initiating Antiretroviral Therapy during Acute HIV Infection. J Clin Micro-
biol 2019; 57:10.
53. Borrell M, Fernández I, Etcheverrry F, Ugarte A, Plana M, Leal L, et al. High rates of long-term progression in HIV-1-positive elite controllers. J Int AIDS Soc. 2021; 24(2):e25675.